Conventional oncological modalities, encompassing external beam radiotherapy, molecularly targeted therapies, and biological immune therapeutics, have substantially advanced patient outcomes; however, they frequently fail to achieve sustained, complete eradication of malignant colognes. These therapeutic interventions typically induce transient tumor cryostasis or partial remission, as malignant cells inevitably undergo clonal evolution and develop multi-drug resistance, thereby compromising long-term therapeutic efficacy. Consequently, the global five-year survival rate across various recalcitrant malignancies stagnates below 60%, underscoring a critical, unmet clinical imperative for novel, definitive therapeutic paradigms. This research article delineates the conceptual framework of Resonance Cancer Elimination (RCE), an innovative biophysical Novel Neutrino Ablation wave-eliminate-shape (Neu-WES) conceptual framework that utilizes specific electromagnetic or corpuscular wavelengths and finely tuned resonance frequencies to achieve highly selective, precise targeting of neoplastic cells. By exploiting the distinct biophysical and bioelectromagnetic properties inherent to malignant phenotypes, this (Neu-WES) methodology induces resonance-mediated disruption of cellular structural integrity and critical metabolic pathways, precipitating selective, irreversible cytolysis at the primary and metastatic sites while preserving adjacent healthy parenchyma. Our novel (Neu-WES) technological and theoretical framework for resonance-based oncology that possesses the potential to supplement or transcend current standard-of-care regimens. This research establishes the theoretical foundations of (RCE) and delineates translational pathways for subsequent potential experimental validation and clinical evaluation, (Neu-WES) representing a paradigm shift toward high-precision, resistance-evasive, and minimally invasive oncological eradication.